Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study

By Colozza M.   Bisagni G.   Mosconi A.M.   Gori S.   Boni C.   Sabbatini R.   Frassoldati A.   Passalacqua R.   Bian A.R.   Rodino C.   Rondini E.   Algeri R.   Di Sarra S.   De Angelis V.   Cocconi G.   Tonato M.   on behalf of the Italian Oncology Group for Clinical Research GOIRC  

European Journal of Cancer, Vol. 38, Iss. 17, 2002-11 ,pp. : 2279-2288

Elsevier

Access to resources Recommend Favorite

Fatigue, Weight Gain, Lethargy and Amenorrhea in Breast Cancer Patients on Chemotherapy: Is Subclinical Hypothyroidism the Culprit?

By Kumar Nagi  

Breast Cancer Research and Treatment, Vol. 83, Iss. 2, 2004-01 ,pp. : 149-159

Springer Publishing Company

Access to resources Recommend Favorite

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

By Coleman R.  

Breast Cancer Research and Treatment, Vol. 127, Iss. 2, 2011-06 ,pp. : 429-438

Springer Publishing Company

Access to resources Recommend Favorite

Selection of Primary Breast Cancer Patients for Adjuvant Endocrine Therapy – is Oestrogen Receptor Alone Adequate?

By Cheung K.L.  

Breast Cancer Research and Treatment, Vol. 65, Iss. 2, 2001-01 ,pp. : 155-162

Springer Publishing Company

Access to resources Recommend Favorite

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden

By Lundkvist Jonas   Wilking Nils   Holmberg Stig   Jönsson Linus  

Breast Cancer Research and Treatment, Vol. 102, Iss. 3, 2007-05 ,pp. : 289-299

Springer Publishing Company

Access to resources Recommend Favorite